farnesyl pyrophosphate

Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid from the mevalonate (MVA) pathway, functions as a metabolic intermediary and TRPM2 (TRP Channel) agonist, facilitating TRPM2 channel opening and ion influx. It is crucial in synthesizing cholesterol, ubiquinones, and geranyl-geranyl pyrophosphate (GGPP), and in protein farnesylation decoration [1].

Farnesyl Pyrophosphate ammonium (Farnesyl diphosphate ammonium) is a metabolic intermediate of the MVA pathway that acts as a newly identified danger signal to trigger acute cell death and induce neuronal loss in stroke.

A-176120 is a potent farnesyl pyrophosphate (FPP) analogues, it selectively inhibits farnesyltransferase. It has anti-angiogenic potential and may reduce H-ras NIH3T3 tumour growth.

A-176120 ammonium is a novel farnesyl pyrophosphate analog with antitumor and antiangiogenic properties and inhibits farnesyltransferase activity.

α-hydroxy Farnesyl phosphonic acid, a nonhydrolyzable analog of farnesyl pyrophosphate, acts as a competitive inhibitor of farnesyl transferase (FTase). At concentrations above 1 μM, it inhibits the processing of Ras in Ha-ras-transformed NIH3T3 cells.

Geranyl pyrophosphate is an intermediate in the mevalonate pathway. It is formed from dimethylallyl pyrophosphate and isopentenyl pyrophosphate by geranyl pyrophosphate synthase. Geranyl pyrophosphate is used in the biosynthesis of farnesyl pyrophosphate , geranylgeranyl pyrophosphate , cholesterol, terpenes, and terpenoids.

Geranylgeranyl pyrophosphate is an intermediate in the HMG-CoA reductase pathway derived directly from farnesyl pyrophosphate and used in the biosynthesis of terpenes and terpenoids.[1] It is also serves as a substrate in the prenylation of a variety of critical intracellular proteins including small GTPases.[2] This post-translational modification is necessary for correct localization of proteins to intracellular membranes for proper functionality and has become a focus of anticancer drug discovery.[3][4]